Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study.
Giulia BonLaura PizzutiValentina LaquintanaRossella LoriaManuela PorruCaterina MarchiòEriseld KrasniqiMaddalena BarbaMarcello Maugeri-SaccàTeresa GamucciRossana BerardiLorenzo LiviCorrado FicorellaClara NatoliEnrico CortesiDaniele GeneraliNicla La VerdeAlessandra CassanoEmilio BriaLuca MoscettiAndrea MichelottiVincenzo AdamoClaudio ZamagniGiuseppe ToniniGiacomo BarchiesiMarco MazzottaDaniele MarinelliSilverio TomaoPaolo MarchettiMaria Rosaria ValerioRosanna MirabelliAntonio RussoMaria Agnese FabbriNicola D'OstilioEnzo VeltriDomenico CorsiOrnella GarroneIda ParisGiuseppina SarobbaFrancesco GiottaCarlo GarufiMarina CazzanigaPietro Del MedicoMario RoselliGiuseppe SanguinetiIsabella SperdutiAnna SapinoRuggero De MariaCarlo LeonettiAngelo Di LeoGennaro CilibertoRita FalcioniPatrizia ViciPublished in: Journal of experimental & clinical cancer research : CR (2020)
Our data support the hypothesis that the addition of pertuzumab to trastuzumab reduces the amount of available plasma membrane HER2 receptor, limiting the binding of T-DM1 in cancer cells. This may help interpret the less favorable outcomes of second-line T-DM1 in trastuzumab/pertuzumab pre-treated patients compared to their pertuzumab-naïve counterpart.
Keyphrases
- epidermal growth factor receptor
- metastatic breast cancer
- newly diagnosed
- end stage renal disease
- ejection fraction
- chronic kidney disease
- tyrosine kinase
- glycemic control
- prognostic factors
- electronic health record
- big data
- machine learning
- metabolic syndrome
- deep learning
- transcription factor
- insulin resistance
- patient reported
- dna binding
- weight loss